SCHEMBL11943222

SCHEMBL11943222

Cc1c(Cl)cccc1C(=O)N1CCN(c2cnn(-c3ccccc3)c(=O)c2NCc2cccnc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ DCTPP1 Q9H773 3/20 0.51
▸ ALDH1A1 P00352 9/20 0.46
▸ MAPT P10636 4/20 0.46
▸ LMNA P02545 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.45
▸ NPBWR1 P48145 1/20 0.43
▸ MCHR1 Q99705 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.42
▸ VNN1 O95497 2/20 0.41
▸ THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13329325 0.93 ALDH1A1 (0.51) DCTPP1ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL11943226 0.83 DCTPP1 (0.44) DCTPP1ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL11943112 0.80 DCTPP1 (0.43) DCTPP1ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL11953028 0.80 ALDH1A1 (0.44) DCTPP1ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL11943292 0.80 MAPT (0.50) DCTPP1ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL11943162 0.80 SMN1; SMN2 (0.41) DCTPP1ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL11943257 0.79 MAPT (0.48) DCTPP1ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL11943117 0.78 ALDH1A1 (0.47) DCTPP1ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL11943132 0.77 MAPT (0.46) DCTPP1ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL11943190 0.76 ALDH1A1 (0.48) DCTPP1ALDH1A1MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2010-06-24 — — US disclosed
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2010-06-24 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA DCTPP1 625/4885ALDH1A1 2437/4885MAPT 2295/4885
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS DPM1, GMPS, MAN2A1 DCTPP1 209/4885ALDH1A1 2003/4885MAPT 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback